Type II JAK2 Inhibitor Gets Off to a Strong Start.
- In the news
AJ1-11095, a type II JAK2 inhibitor, shows promising clinical responses in myelofibrosis, outperforming existing type I JAK2 inhibitors in early trials.
- Why it matters: Effective treatments for myelofibrosis are limited, and current JAK2 inhibitors often have suboptimal responses or side effects, creating a need for improved therapies.
- What they did: Researchers conducted a phase I study of AJ1-11095, testing its safety and efficacy in patients with myelofibrosis, with initial results indicating strong clinical activity.
- The result: The promising responses suggest AJ1-11095 could surpass current treatments, paving the way for further development and potential new standards in myelofibrosis therapy.